HIV-associated multicentric Castleman's disease

American Journal of Hematology

Volumn 83, Issue 6, 2008, Pages 498-503

  Stebbing, Justin ^a   Pantanowitz, Liron ^b   Dayyani, Farshid ^c   Sullivan, Ryan J ^c   Bower, Mark ^d   Dezube, Bruce J ^c,e  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALTIZUMAB; BLEOMYCIN; C REACTIVE PROTEIN; CHLORAMBUCIL; CIDOFOVIR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FOSCARNET; GANCICLOVIR; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOGLOBULIN M; INTERLEUKIN 10; INTERLEUKIN 6; MONOCLONAL ANTIBODY; PREDNISONE; RITUXIMAB; VALGANCICLOVIR; VINBLASTINE; VINCRISTINE;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; B LYMPHOCYTE; CLINICAL FEATURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPATHOGENESIS; KAPOSI SARCOMA; LYMPH NODE BIOPSY; LYMPHADENECTOMY; LYMPHOCYTE DEPLETION HODGKIN LYMPHOMA; MONOTHERAPY; PRIORITY JOURNAL; REVIEW; SPLENECTOMY; VIRUS CARCINOGENESIS;

GIANT LYMPH NODE HYPERPLASIA; HERPESVIRUS 8, HUMAN; HIV INFECTIONS; HIV-1; HUMANS;

EID: 44349109438     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21137     Document Type: Review

References (94)

1. Castleman B, Towne VW. Case records of the Massachusetts general hospital: Case No. 40231. N Engl J Med 1954;250:1001-1005.
2. Castleman B, Iverson L, Menendez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer 1956;9:822-830.
3. Soulier J, Grollet L, Oksenhendler E, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 1995;86:1276-1280.
4. Stebbing J, Bower M. What can oncologists learn from HIV? Lancet Oncol 2003;4:438-445.
5. Oksenhendler E, Duarte M, Soulier J, et al. Multicentric Castleman's disease in HIV infection: A clinical and pathological study of 20 patients. AIDS 1996;10:61-67.
6. Bowne WB, Lewis JJ, Filippa DA, et al. The management of unicentric and multicentric Castleman's disease: A report of 16 cases and a review of the literature. Cancer 1999;85:706-717.
7. Casper C, Nichols WG, Huang ML, et al. Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment. Blood 2004;103:1632-1634.
8. Nishimoto N, Sasai M, Shima Y, et al. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 2000;95:56-61.
9. Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 2005;106:2627-2632.
10. Colleoni GW, Duarte LC, Kerbauy FR, et al. 2-Chloro-deoxyadenosine induces durable complete remission in Castleman's disease but may accelerate its transformation to non-Hodgkin's lymphoma. Acta Oncol 2003;42:784-787.
11. Soulier J, Grollet L, Oksenhendler E, et al. Molecular analysis of clonality in Castleman's disease. Blood 1995;86:1131-1138.
12. Ide M, Kawachi Y, Izumi Y, et al. Long-term remission in HIV-negative patients with multicentric Castleman's disease using rituximab. Eur J Haematol 2006;76:119-123.
13. Neuville S, Agbalika F, Rabian C, et al. Failure of rituximab in human immunodeficiency virus-associated multicentric Castleman disease. Am J Hematol 2005;79:337-339.
14. Dupin N, Diss TL, Kellam P, et al. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood 2000;95(4):1406-1412.
15. Ioachim HL, Ratech H. Ioachim's Lymph Node Pathology. Philadelphia: Lippincott, Williams & Wilkins; 2002. pp 246-253.
16. Ota T, Mitsuyoshi A, Zaima M, et al. Visualization of central stellate fibrosis in hyaline vascular type Castleman's disease. Br J Radiol 1997;70:1060-1062.
17. Goetze O, Banasch M, Junker K, et al. Unicentric Castleman's disease of the pancreas with massive central calcification. World J Gastroenterol 2005;11:6725-6727.
18. Kreft A, Weber A, Springer E, et al. Bone marrow findings in multicentric Castleman disease in HIV-negative patients. Am J Surg Pathol 2007;31:398-402.
19. Molina T, Brouland JP, Bigorgne C, et al. [Pseudo-myelomatous plasmacytosis of the bone marrow in a multicentric Castleman's disease]. Ann Pathol 1996;16:133-136.
20. Bacon CM, Miller RF, Noursadeghi M, et al. Pathology of bone marrow in human herpes virus-8 (HHV8)-associated multicentric Castleman disease. Br J Haematol 2004;127:585-591.
21. Frizzera G. Atypical lymphoproliferative disorders. In: Neoplastic Hematopathology. Knowles DM, editor. Philadelphia; Lippincott, Williams & Wilkins; 2001. pp 569-622.
22. Johkoh T, Muller NL, Ichikado K, et al. Intrathoracic multicentric Castleman disease: CT findings in 12 patients. Radiology 1998;209:477-481.
23. Kojima M, Nakamura S, Shimizu K, et al. Nodal marginal zone B-cell lymphoma resembling plasmacytoma arising from a plasma cell variant of localized Castleman's disease: A case report. APMIS 2002;110(7/8):523-527.
24. Venizelos I, Tamiolakis D, Simopoulos C, et al. Diffuse large B-cell lymphoma arising from a multicentric mixed variant of Castleman's disease. Indian J Cancer 2004;41:135-137.
25. Chan JK, Tsang WY, Ng CS. Follicular dendritic cell tumor and vascular neoplasm complicating hyaline-vascular Castleman's disease. Am J Surg Pathol 1994;18:517-525.
26. Zarate-Osorno A, Medeiros LJ, Danon AD, et al. Hodgkin's disease with coexistent Castleman-like histologic features. A report of three cases. Arch Pathol Lab Med 1994;118:270-274.
27. Stebbing J, Wilder N, Ariad S, et al. Lack of intra-patient strain variability during infection with Kaposi's sarcoma-associated herpesvirus. Am J Hematol 2001;68:133-134.
28. Day JR, Bew D, Ali M, et al. Castleman's disease associated with myasthenia gravis. Ann Thorac Surg 2003;75:1648-1650.
29. Papo T, Soubrier M, Marcelin AG, et al. Human herpesvirus 8 infection, Castleman's disease and POEMS syndrome. Br J Haematol 1999;104:932-933.
30. Pasaoglu I, Dogan R, Topcu M, et al. Multicentric angiofollicular lymph-node hyperplasia associated with myasthenia gravis. Thorac Cardiovasc Surg 1994;42:253-256.
31. Waterston A, Bower M. Fifty years of multicentric Castleman's disease. Acta Oncol 2004;43:698-704.
32. Ribeiro LT, Simao GN, Matos AL, et al. Intracranial Castleman's disease presenting as hypopituitarism. Neuroradiology 2004;46:830-833.
33. Chim CS, Choi FP, Ooi GC, et al. Absence of gallium uptake in multicentric Castleman's disease of plasma cell type. Haematologica 2001;86:442-443.
34. Enomoto K, Nakamichi I, Hamada K, et al. Unicentric and multicentric Castleman's disease. Br J Radiol 2007;80:e24-e26.
35. Aoki Y, Tosato G, Fonville TW, et al. Serum viral interleukin-6 in AIDS-related multicentric Castleman disease. Blood 2001;97:2526-2527.
36. Choi J, Means RE, Damania B, et al. Molecular piracy of Kaposi's sarcoma associated herpesvirus. Cytokine Growth Factor Rev 2001;12(2/3):245-257.
37. Said J. Kaposi's sarcoma-associated herpesvirus (KSHV): A new viral pathogen associated with Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. West J Med 1997;167:37-38.
38. Du MQ, Liu H, Diss TC, et al. Kaposi sarcoma-associated herpesvirus infects monotypic (IgM λ) but polyclonal naive B cells in Castleman disease and associated lymphoproliferative disorders. Blood 2001;97:2130-2136.
39. van Kooten C, Rensink I, Aarden L, et al. Effect of IL-4 and IL-6 on the proliferation and differentiation of B-chronic lymphocytic leukemia cells. Leukemia 1993;7:618-624.
40. Yokoi T, Miyawaki T, Yachie A, et al. Epstein-Barr virus-immortalized B cells produce IL-6 as an autocrine growth factor. Immunology 1990;70:100-105.
41. Brandt SJ, Bodine DM, Dunbar CE, et al. Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice. J Clin Invest 1990;86:592-599.
42. Screpanti I, Musiani P, Bellavia D, et al. Inactivation of the IL-6 gene prevents development of multicentric Castleman's disease in C/EBP β-deficient mice. J Exp Med 1996;184:1561-1566.
43. Deng H, Song MJ, Chu JT, et al. Transcriptional regulation of the interleukin-6 gene of human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus). J Virol 2002;76:8252-8264.
44. An J, Lichtenstein AK, Brent G, et al. The Kaposi sarcoma-associated herpesvirus (KSHV) induces cellular interleukin 6 expression: Role of the KSHV latency-associated nuclear antigen and the AP1 response element. Blood 2002;99:649-654.
45. Hsu SM, Waldron JA, Xie SS, et al. Expression of interleukin-6 in Castleman's disease. Hum Pathol 1993;24:833-839.
46. Oksenhendler E, Boulanger E, Galicier L, et al. High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease. Blood 2002;99:2331-2336.
47. Russo JJ, Bohenzky RA, Chien MC, et al. Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc Natl Acad Sci USA 1996;93:14862-14867.
48. Song J, Ohkura T, Sugimoto M, et al. Human interleukin-6 induces human herpesvirus-8 replication in a body cavity-based lymphoma cell line. J Med Virol 2002;68:404-411.
49. Staskus KA, Sun R, Miller G, et al. Cellular tropism and viral interleukin-6 expression distinguish human herpesvirus 8 involvement in Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. J Virol 1999;73:4181-4187.
50. Boulanger MJ, Chow DC, Brevnova E, et al. Molecular mechanisms for viral mimicry of a human cytokine: Activation of gp130 by HHV-8 interleukin-6. J Mol Biol 2004;335:641-654.
51. Li H, Wang H, Nicholas J. Detection of direct binding of human herpesvirus 8-encoded interleukin-6 (vIL-6) to both gp130 and IL-6 receptor (IL-6R) and identification of amino acid residues of vIL-6 important for IL-6R-dependent and -independent signaling. J Virol 2001;75:3325-3334.
52. Molden J, Chang Y, You Y, et al. A Kaposi's sarcoma-associated herpesvirus-encoded cytokine homolog (vIL-6) activates signaling through the shared gp130 receptor subunit. J Biol Chem 1997;272:19625-19631.
53. Aoki Y, Jaffe ES, Chang Y, et al. Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. Blood 1999;93:4034-4043.
54. Oksenhendler E, Carcelain G, Aoki Y, et al. High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric castleman disease in HIV-infected patients. Blood 2000;96:2069-2073.
55. Newsom-Davis T, Bower M, Wildfire A, et al. Resolution of AIDS-related Castleman's disease with anti-CD20 monoclonal antibodies is associated with declining IL-6 and TNF-α levels. Leuk Lymphoma 2004;45:1939-1941.
56. Dupin N, Fisher C, Kellam P, et al. Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc Natl Acad Sci USA 1999;96:4546-4551.
57. Pereira TC, Landreneau R, Nathan G, et al. Pathologic quiz case. Large posterior mediastinal mass in a young woman. Pathologic diagnosis: Localized hyaline-vascular-type Castleman disease (angiofollicular lymphoid hyperplasia). Arch Pathol Lab Med 2001;125:964-967.
58. Izumi M, Mochizuki M, Kuroda M, et al. Angiomyoid proliferative lesion: An unusual stroma-rich variant of Castleman's disease of hyaline-vascular type. Virchows Arch 2002;441:400-405.
59. Dargent JL, Delplace J, Roufosse C, et al. Development of a calcifying fibrous pseudotumour within a lesion of Castleman disease, hyaline-vascular subtype. J Clin Pathol 1999;52:547-549.
60. Danon AD, Krishnan J, Frizzera G. Morpho-immunophenotypic diversity of Castleman's disease, hyaline-vascular type: With emphasis on a stroma-rich variant and a new pathogenetic hypothesis. Virchows Arch A Pathol Anat Histopathol 1993;423:369-382.
61. Menke DM, Tiemann M, Camoriano JK, et al. Diagnosis of Castleman's disease by identification of an immunophenotypically aberrant population of mantle zone B lymphocytes in paraffin-embedded lymph node biopsies. Am J Clin Pathol 1996;105:268-276.
62. Kim JE, Kim CJ, Park IA, et al. Clinicopathologic study of Castleman's disease in Korea. J Korean Med Sci 2000;15:393-398.
63. O'Leary J, Kennedy M, Howells D, et al. Cellular localisation of HHV-8 in Castleman's disease: Is there a link with lymph node vascularity? Mol Pathol 2000;53:69-76.
64. Valmary S, Richard P, Brousset P. Frequent detection of Kaposi's sarcoma herpesvirus in germinal centre macrophages from AIDS-related multicentric Castleman's disease. AIDS 2005;19:1229-1231.
65. Scadden DT, Muse VV, Hasserjian RP. Case records of the Massachusetts general hospital. Case 30-2006. A 41-year-old man with dyspnea, fever, and lymphadenopathy. N Engl J Med 2006;355:1358-1368.
66. Hanson CA, Frizzera G, Patton DF, et al. Clonal rearrangement for immunoglobulin and T-cell receptor genes in systemic Castleman's disease. Association with Epstein-Barr virus. Am J Pathol 1988;131:84-91.
67. Murray PG, Deacon E, Young LS, et al. Localization of Epstein-Barr virus in Castleman's disease by in situ hybridization and immunohistochemistry. Hematol Pathol 1995;9:17-26.
68. Gerard L, Berezne A, Galicier L, et al. Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial. J Clin Oncol 2007;25:3350-3356.
69. Bower M, Powles T, Williams S, Davis TN, Atkins M, Montoto S, Orkin C, Webb A, Fisher M, Nelson M, Gazzard B, Stebbing J, Kelleher P. Rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med 2007;147:836-839.
70. Scott D, Cabral L, Harrington WJ Jr. Treatment of HIV-associated multicentric Castleman's disease with oral etoposide. Am J Hematol 2001;66:148-150.
71. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-860.
72. Bower M, Fox P, Fife K, et al. Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma. AIDS 1999;13:2105-2111.
73. Portsmouth S, Stebbing J, Gill J, et al. A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma. AIDS 2003;17:F17-F22.
74. Aaron L, Lidove O, Yousry C, et al. Human herpesvirus 8-positive Castleman disease in human immunodeficiency virus-infected patients: The impact of highly active antiretroviral therapy. Clin Infect Dis 2002;35:880-882.
75. Zietz C, Bogner JR, Goebel FD, et al. An unusual cluster of cases of Castleman's disease during highly active antiretroviral therapy for AIDS. N Engl J Med 1999;340:1923-1924.
76. Nord JA, Karter D. Low dose interferon-alpha therapy for HIV-associated multicentric Castleman's disease. Int J STD AIDS 2003;14:61-62.
77. Strohal R, Tschachler E, Breyer S, et al. Reactivation of Behcet's disease in the course of multicentric HHV8-positive Castleman's disease: Long-term complete remission by a combined chemo/radiation and interferon-α therapy regimen. Br J Haematol 1998;103:788-790.
78. Lebbe C, Agbalika F, de Cremoux P, et al. Detection of human herpesvirus 8 and human T-cell lymphotropic virus type 1 sequences in Kaposi sarcoma. Arch Dermatol 1997;133:25-30.
79. Kumari P, Schechter GP, Saini N, et al. Successful treatment of human immunodeficiency virus-related Castleman's disease with interferon-α. Clin Infect Dis 2000;31:602-604.
80. Jung CP, Emmerich B, Goebel FD, et al. Successful treatment of a patient with HIV-associated multicentric Castleman disease (MCD) with thalidomide. Am J Hematol 2004;75:176-177.
81. Lee FC, Merchant SH. Alleviation of systemic manifestations of multicentric Castleman's disease by thalidomide. Am J Hematol 2003;73:48-53.
82. Martin DF, Kuppermann BD, Wolitz RA, et al. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. N Engl J Med 1999;340:1063-1070.
83. Mazzi R, Parisi SG, Sarmati L, et al. Efficacy of cidofovir on human herpesvirus 8 viraemia and Kaposi's sarcoma progression in two patients with AIDS. AIDS 2001;15:2061-2062.
84. Low P, Neipel F, Rascu A, et al. Suppression of HHV-8 viremia by foscarnet in an HIV-infected patient with Kaposi's sarcoma and HHV-8 associated hemophagocytic syndrome. Eur J Med Res 1998;3:461-464.
85. Luppi M, Barozzi P, Rasini V, et al. Severe pancytopenia and hemophagocytosis after HHV-8 primary infection in a renal transplant patient successfully treated with foscarnet. Transplantation 2002;74:131-132.
86. Senanayake S, Kelly J, Lloyd A, et al. Multicentric Castleman's disease treated with antivirals and immunosuppressants. J Med Virol 2003;71:399-403.
87. Valencia ME, Moreno V, Martinez P, et al. [Favorable outcome of Castleman's disease treated with oral valganciclovir]. Med Clin (Barc) 2005;125:399.
88. Corbellino M, Bestetti G, Scalamogna C, et al. Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. Blood 2001;98:3473-3475.
89. Marcelin AG, Aaron L, Mateus C, et al. Rituximab therapy for HIV-associated Castleman disease. Blood 2003;102:2786-2788.
90. Marrache F, Larroche C, Memain N, et al. Prolonged remission of HIV-associated multicentric Castelman's disease with an anti-CD20 monoclonal antibody as primary therapy. AIDS 2003;17:1409-1410.
91. Kofteridis DP, Tzagarakis N, Mixaki I, et al. Multicentric Castleman's disease: Prolonged remission with anti CD-20 monoclonal antibody in an HIV-infected patient. AIDS 2004;18:585-586.
92. Dayyani F, Pantanowitz L, Sandridge TG, et al. Multicentric Castleman's disease masquerading as HIV-related lymphoma. Am J Med Sci 2007;334:317-319.
93. Powles T, Stebbing J, Montoto S, et al. Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman disease. Blood 2007;110:4132-4133.
94. Bower M, Nelson M, Young AM, et al. Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma. J Clin Oncol 2005;23:5224-5228.